View in EDS

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.

Saved in:
Bibliographic Details
Title: Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.
Authors: Einsele H; Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany. Electronic address: einsele_h@ukw.de., San-Miguel J; Cancer Center Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain., Dhakal B; Medical College of Wisconsin, Milwaukee, WI, USA., Touzeau C; Service d'Hématologie, CHU Hotel Dieu, Nantes, France; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France; Site de Recherche Intégrée sur le Cancer (SIRIC), ILIAD, INCA-DGOS-Inserm_12558, Nantes, France., Leleu X; Service d'Hématologie et Thérapie Cellulaire, Hôpital La Milétrie, Poitiers University Hospital, Poitiers, France; Centre d'Investigation Clinique INSERM 1402, Poitiers University Hospital, Poitiers, France., van de Donk NW; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Sidana S; Stanford University School of Medicine, Stanford, CA, USA., Oriol A; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain; Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain., Cohen YC; Tel-Aviv Sourasky (Ichilov) Medical Center, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel., Harrison SJ; Peter MacCallum Cancer Centre, Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia; Translation Laboratory, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia., Mateos MV; University Hospital of Salamanca-IBSAL-CIC-CIBERONC, Salamanca, Spain., Martínez-López J; Hospital 12 de Octubre, Complutense University CNIO, MIC, Madrid, Spain., Corradini P; Fondazione IRCCS Istituto Nazionale dei Tumori Milano, University of Milano, Milan, Italy., Karlin L; Centre Hospitalier Lyon Sud, Pierre-Bénite, France., Chen D; Johnson & Johnson, Shanghai, China., Li Q; Johnson & Johnson, Apex, NC, USA., Yeh TM; Johnson & Johnson, Raritan, NJ, USA., Li K; Johnson & Johnson, Spring House, PA, USA., Plaks V; Johnson & Johnson, Spring House, PA, USA., Slaughter A; Johnson & Johnson, Zug, Switzerland., Lonardi C; Johnson & Johnson, Buenos Aires, Argentina., Benachour N; Johnson & Johnson, Beerse, Belgium., Ghosh A; Johnson & Johnson, Raritan, NJ, USA., Vogel M; Johnson & Johnson, Neuss, Germany., Schecter JM; Johnson & Johnson, Raritan, NJ, USA., Lendvai N; Johnson & Johnson, Raritan, NJ, USA., Koneru M; Legend Biotech USA, Somerset, NJ, USA., Patel N; Legend Biotech USA, Somerset, NJ, USA., Florendo E; Legend Biotech USA, Somerset, NJ, USA., Ho PJ; Royal Prince Alfred Hospital, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia., Popat R; University College London Hospitals, NHS Foundation Trust, London, UK.
Source: The Lancet. Oncology [Lancet Oncol] 2026 Feb; Vol. 27 (2), pp. 254-268. Date of Electronic Publication: 2026 Jan 07.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41519141
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Einsele+H%22">Einsele H</searchLink>; Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany. Electronic address: einsele_h@ukw.de.<br /><searchLink fieldCode="AU" term="%22San-Miguel+J%22">San-Miguel J</searchLink>; Cancer Center Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Dhakal+B%22">Dhakal B</searchLink>; Medical College of Wisconsin, Milwaukee, WI, USA.<br /><searchLink fieldCode="AU" term="%22Touzeau+C%22">Touzeau C</searchLink>; Service d'Hématologie, CHU Hotel Dieu, Nantes, France; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France; Site de Recherche Intégrée sur le Cancer (SIRIC), ILIAD, INCA-DGOS-Inserm_12558, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; Service d'Hématologie et Thérapie Cellulaire, Hôpital La Milétrie, Poitiers University Hospital, Poitiers, France; Centre d'Investigation Clinique INSERM 1402, Poitiers University Hospital, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22van+de+Donk+NW%22">van de Donk NW</searchLink>; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Sidana+S%22">Sidana S</searchLink>; Stanford University School of Medicine, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Oriol+A%22">Oriol A</searchLink>; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain; Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.<br /><searchLink fieldCode="AU" term="%22Cohen+YC%22">Cohen YC</searchLink>; Tel-Aviv Sourasky (Ichilov) Medical Center, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Harrison+SJ%22">Harrison SJ</searchLink>; Peter MacCallum Cancer Centre, Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia; Translation Laboratory, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; University Hospital of Salamanca-IBSAL-CIC-CIBERONC, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Martínez-López+J%22">Martínez-López J</searchLink>; Hospital 12 de Octubre, Complutense University CNIO, MIC, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Corradini+P%22">Corradini P</searchLink>; Fondazione IRCCS Istituto Nazionale dei Tumori Milano, University of Milano, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Karlin+L%22">Karlin L</searchLink>; Centre Hospitalier Lyon Sud, Pierre-Bénite, France.<br /><searchLink fieldCode="AU" term="%22Chen+D%22">Chen D</searchLink>; Johnson & Johnson, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Li+Q%22">Li Q</searchLink>; Johnson & Johnson, Apex, NC, USA.<br /><searchLink fieldCode="AU" term="%22Yeh+TM%22">Yeh TM</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Li+K%22">Li K</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Plaks+V%22">Plaks V</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Slaughter+A%22">Slaughter A</searchLink>; Johnson & Johnson, Zug, Switzerland.<br /><searchLink fieldCode="AU" term="%22Lonardi+C%22">Lonardi C</searchLink>; Johnson & Johnson, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Benachour+N%22">Benachour N</searchLink>; Johnson & Johnson, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Ghosh+A%22">Ghosh A</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Vogel+M%22">Vogel M</searchLink>; Johnson & Johnson, Neuss, Germany.<br /><searchLink fieldCode="AU" term="%22Schecter+JM%22">Schecter JM</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Lendvai+N%22">Lendvai N</searchLink>; Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Koneru+M%22">Koneru M</searchLink>; Legend Biotech USA, Somerset, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Patel+N%22">Patel N</searchLink>; Legend Biotech USA, Somerset, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Florendo+E%22">Florendo E</searchLink>; Legend Biotech USA, Somerset, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Ho+PJ%22">Ho PJ</searchLink>; Royal Prince Alfred Hospital, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Popat+R%22">Popat R</searchLink>; University College London Hospitals, NHS Foundation Trust, London, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2026 Feb; Vol. 27 (2), pp. 254-268. <i>Date of Electronic Publication: </i>2026 Jan 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41519141
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(25)00653-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 254
    Titles:
      – TitleFull: Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Einsele H
      – PersonEntity:
          Name:
            NameFull: San-Miguel J
      – PersonEntity:
          Name:
            NameFull: Dhakal B
      – PersonEntity:
          Name:
            NameFull: Touzeau C
      – PersonEntity:
          Name:
            NameFull: Leleu X
      – PersonEntity:
          Name:
            NameFull: van de Donk NW
      – PersonEntity:
          Name:
            NameFull: Sidana S
      – PersonEntity:
          Name:
            NameFull: Oriol A
      – PersonEntity:
          Name:
            NameFull: Cohen YC
      – PersonEntity:
          Name:
            NameFull: Harrison SJ
      – PersonEntity:
          Name:
            NameFull: Mateos MV
      – PersonEntity:
          Name:
            NameFull: Martínez-López J
      – PersonEntity:
          Name:
            NameFull: Corradini P
      – PersonEntity:
          Name:
            NameFull: Karlin L
      – PersonEntity:
          Name:
            NameFull: Chen D
      – PersonEntity:
          Name:
            NameFull: Li Q
      – PersonEntity:
          Name:
            NameFull: Yeh TM
      – PersonEntity:
          Name:
            NameFull: Li K
      – PersonEntity:
          Name:
            NameFull: Plaks V
      – PersonEntity:
          Name:
            NameFull: Slaughter A
      – PersonEntity:
          Name:
            NameFull: Lonardi C
      – PersonEntity:
          Name:
            NameFull: Benachour N
      – PersonEntity:
          Name:
            NameFull: Ghosh A
      – PersonEntity:
          Name:
            NameFull: Vogel M
      – PersonEntity:
          Name:
            NameFull: Schecter JM
      – PersonEntity:
          Name:
            NameFull: Lendvai N
      – PersonEntity:
          Name:
            NameFull: Koneru M
      – PersonEntity:
          Name:
            NameFull: Patel N
      – PersonEntity:
          Name:
            NameFull: Florendo E
      – PersonEntity:
          Name:
            NameFull: Ho PJ
      – PersonEntity:
          Name:
            NameFull: Popat R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2026 Feb
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1